The Conversation (0)
JAMA Oncology Publication Demonstrates EndoPredict Significantly Outperforms Oncotype DX
Feb. 15, 2018 09:30AM PST
Genetics InvestingMyriad Genetics (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology. A key finding is that Myriad’s EndoPredict® (EPClin) significantly outperformed Oncotype DX® Recurrence Score at predicting the risk of disease recurrence in patients with early-stage breast cancer. As quoted in …
Myriad Genetics (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology. A key finding is that Myriad’s EndoPredict® (EPClin) significantly outperformed Oncotype DX® Recurrence Score at predicting the risk of disease recurrence in patients with early-stage breast cancer.
As quoted in the press release:
“This study demonstrates that EndoPredict, which combines a multigene signature with clinical information, significantly improves the prediction of disease recurrence, specifically in women with node-positive breast cancer,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics. “What this means is that EndoPredict can more accurately identify a larger percentage of patients who can safely forgo adjuvant chemotherapy and the associated toxicity.”